Sterling Capital Management’s TG Therapeutics TGTX Stock Holding History

Sterling Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.1K	Sell	511 -430	-46%	-$17.6K	﹤0.01%	1741
2026 Q1	$31.3K	Sell	941 -1	-0.1%	-$30	﹤0.01%	1827
2025 Q4	$28.1K	Buy	942 +590	+168%	+$19.3K	﹤0.01%	2052
2025 Q3	$12.7K	Sell	352 -5	-1%	-$165	﹤0.01%	2365
2025 Q2	$12.8K	Buy	357 +212	+146%	+$7.89K	﹤0.01%	1978
2025 Q1	$5.72K	Buy	145 +4	+3%	+$135	﹤0.01%	2098
2024 Q4	$4.24K	Sell	141 -1	-0.7%	-$29	﹤0.01%	2534
2024 Q3	$3.32K	Buy	+142	New	+$3.1K	﹤0.01%	1941

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Sterling Capital Management's TGTX Position: Q2 2026 in Review

Sterling Capital Management reduced its TG Therapeutics (TGTX) stake by 46% in Q2 2026, selling an estimated $17.6K and leaving 511 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Sterling Capital Management first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $31.3K in Q1 2026. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Sterling Capital Management held 511 shares of TG Therapeutics worth $28.1K as of Q2 2026.
Sterling Capital Management sold 430 TG Therapeutics shares in Q2 2026, an estimated $17.6K.
TG Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1741 holding.
Sterling Capital Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's TG Therapeutics position peaked at $31.3K in Q1 2026.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.